Shandong Weigao Group Medical Polymer Company Limited disclosed that on 12 June 2026 it repurchased 80,000 H shares on the Hong Kong Stock Exchange at prices between HK$3.34 and HK$3.36, for a total consideration of HK$0.27 million. The shares were retained as treasury stock.

Following the transaction, the company’s issued shares (excluding treasury shares) fell to 4,464,266,324, representing a 0.0018% reduction from the previous day. Treasury shares rose to 58,066,000, while the total issued share count remained unchanged at 4,522,332,324.

The buy-back forms part of a mandate approved on 29 May 2026 that authorises repurchases of up to 446.46 million shares. Including the latest purchase, 740,000 shares—equivalent to 0.17% of the issued share count on the mandate date—have been repurchased under this authority.

Under Hong Kong listing rules, the company is restricted from issuing new shares or disposing of treasury shares until 12 July 2026.